Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.
Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.
Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.
Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.
Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.
You may not be if
Has been permanently discontinued from study treatment in the parent study for any reason.
Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
Pregnant or breastfeeding woman.
Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.
Clareo Health | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
